DRREDDY - Dr. Reddy's Laboratories Ltd. Share Price

Pharmaceuticals & Biotechnology

₹1198.70+23.90(+2.03%)

Market Closed as of Apr 28, 2025, 15:30 IST

What does Dr. Reddy's Laboratories Ltd. do?

Pharmaceuticals•Healthcare•Large Cap

Dr. Reddy's Lab is a prominent pharmaceuticals company, trading under the stock ticker DRREDDY, with a substantial market capitalization of Rs. 94,561.1 Crores.

Located in Hyderabad, India, and incorporated in 1984, Dr. Reddy's operates as an integrated pharmaceutical company on a global scale, managing its operations through several key segments:

Global Generics: This segment focuses on the manufacture and marketing of prescription and over-the-counter pharmaceutical products, whether branded or generic. It also involves the biologics business.
Pharmaceutical Services and Active Ingredients (PSAI): Here, the company manufactures and markets active pharmaceutical ingredients and intermediates which are essential components of finished pharmaceutical products. Additionally, this segment provides contract research services and custom manufacturing for clients.
Others: This area delves into the development of therapies in oncology and inflammation, the research of differentiated formulations, and the provision of digital healthcare and IT-enabled business support services.

Dr. Reddy's Lab has generated a trailing 12 months revenue of Rs. 32,071.7 Crores, indicating strong financial performance with a notable profit of Rs. 5,448.3 Crores over the last four quarters.

The company serves various therapeutic categories, including gastrointestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, showcasing its diverse product offerings.

Moreover, Dr. Reddy's offers dividends to its investors, boasting a 0.6% dividend yield and having returned Rs. 8 in dividends per share over the past year. Despite experiencing a 0.3% dilution of shareholder holdings in the past three years, the company has enjoyed 50.6% revenue growth in the same period, reaffirming its profitable standing in the pharmaceutical industry.

Industry Group:Pharmaceuticals & Biotechnology

Employees:27,048

Website:www.drreddys.com

Latest News and Updates from Dr. Reddy's Lab

Updated Apr 28, 2025

Dr. Reddy's Laboratories (BSE: DRREDDY) has shown mixed performance in recent trading sessions, experiencing gains in stock price alongside broader market fluctuations. The company has been facing challenges, including a product recall classified as Class 1 by the USFDA, raising compliance concerns. Despite these issues, there are positive indicators in terms of historical stock performance and investor interest. Overall, the situation reflects a balance of positive growth potential and negative compliance hurdles.

The Bad News

Devdiscourse

Dr. Reddy's Laboratories is recalling 4,010 bags of Levetiracetam injection in the US due to a labeling error, which may impact its reputation.

Markets Insider

The company has also faced claims regarding a 25% reduction in workforce costs, which it has categorically denied, aiming to correct misinformation.

DNA India

Dr. Reddy's is dealing with a proposed tax demand exceeding Rs 2,395 crore from the income tax authority regarding a merger.

The Good News

moneycontrol.com

Dr. Reddy's Laboratories saw a significant rise of 2.90% to Rs 1,142.60 today, indicating strong investor interest and market activity.

The Financial Express

Over the past week, Dr. Reddy's stock has gained 3.55%, highlighting its resilience amidst market fluctuations.

The Financial Express

Dr. Reddy's has performed positively over three and five years, with gains of 46.53% and 50.54%, respectively.

This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.

Pros

Insider Trading: There's significant insider buying recently.

Growth: Good revenue growth. With 50.6% growth over past three years, the company is going strong.

Balance Sheet: Strong Balance Sheet.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Size: It is among the top 200 market size companies of india.

Smart Money: Smart money has been increasing their position in the stock.

Profitability: Very strong Profitability. One year profit margin are 17%.

Cons

No major cons observed.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Sector Comparison: DRREDDY vs Pharmaceuticals & Biotechnology

Comprehensive comparison against sector averages

Comparative Metrics

DRREDDY metrics compared to Pharmaceuticals

Category	DRREDDY	Pharmaceuticals
PE	17.99	37.19
PS	3.06	5.23
Growth	14.3 %	7.1 %

Performance Comparison

DRREDDY vs Pharmaceuticals (2021 - 2025)

Key Insights

1. DRREDDY is among the Top 10 Pharmaceuticals companies but not in Top 5.
2. The company holds a market share of 7.8% in Pharmaceuticals.
3. In last one year, the company has had an above average growth that other Pharmaceuticals companies.

Cash Flow for Dr. Reddy's Lab

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	31.2%	22	17	38
Change in inventories	-1105.9%	-1,217	-100	-528.1
Depreciation	5.7%	976	923	814
Impairment loss / reversal	509.8%	26	5.1	9.8
Unrealised forex losses/gains	104%	7.6	-165.6	-162.3
Dividend income	-	45	0	0
Adjustments for interest income	135.7%	305	130	167
Share-based payments	9.7%	35	32	59
Net Cashflows from Operations	-18.3%	4,769	5,836	1,828
Income taxes paid (refund)	68.7%	1,320	783	489
Net Cashflows From Operating Activities	-31.7%	3,450	5,053	1,339
Cashflows used in obtaining control of subsidiaries	75.6%	80	46	0
Proceeds from sales of PPE	-104.2%	0	25	9.4
Purchase of property, plant and equipment	36.1%	1,361	1,000	1,311
Proceeds from sales of investment property	-	88	0	0
Purchase of intangible assets	-59.5%	232	571	54
Dividends received	-	45	0	0
Interest received	82.8%	182	100	157
Other inflows (outflows) of cash	-	-60.6	0	0
Net Cashflows From Investing Activities	0.5%	-3,430.3	-3,447.6	-2,038
Proceeds from issuing shares	426.7%	80	16	33
Proceeds from borrowings	-	709	0	968
Repayments of borrowings	-100%	0	2,170	0
Payments of lease liabilities	-105.3%	0	20	17
Dividends paid	33.6%	665	498	415
Interest paid	-28.9%	33	46	64
Other inflows (outflows) of cash	-105%	0	21	0
Net Cashflows from Financing Activities	102.5%	68	-2,696.9	506
Effect of exchange rate on cash eq.	-98.6%	1.6	44	48
Net change in cash and cash eq.	108.4%	89	-1,047.2	-145.9

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	19.7%	171	143	96
Change in inventories	-592.8%	-1,844.5	-265.4	-532.8
Depreciation	17.6%	1,470	1,250	1,165
Impairment loss / reversal	-101%	0.3	70	930
Unrealised forex losses/gains	41.9%	-53.3	-92.5	-75.8
Adjustments for interest income	94%	228	118	96
Share-based payments	2.6%	41	40	59
Net Cashflows from Operations	-5.9%	6,548	6,959	3,554
Income taxes paid (refund)	87.3%	2,005	1,071	744
Net Cashflows From Operating Activities	-22.8%	4,543	5,887	2,811
Cashflows used in obtaining control of subsidiaries	-	0	0	33
Cash payment for investment in partnership firm or association of persons or LLP	-	1.2	0	0
Proceeds from sales of PPE	1358.3%	106	8.2	37
Purchase of property, plant and equipment	44.9%	1,640	1,132	1,466
Proceeds from sales of intangible assets	-	0	0	295
Purchase of intangible assets	46.3%	1,103	754	439
Dividends received	-	44	0	0
Interest received	72.7%	134	78	87
Net Cashflows From Investing Activities	2.6%	-4,028.3	-4,137.1	-2,638.7
Proceeds from issuing shares	426.7%	80	16	33
Proceeds from borrowings	-	929	0	352
Repayments of borrowings	-80.4%	380	1,938	0
Payments of lease liabilities	12.9%	115	102	78
Dividends paid	33.6%	665	498	415
Interest paid	22.8%	227	185	134
Other inflows (outflows) of cash	-105%	0	21	0
Net Cashflows from Financing Activities	86%	-376.3	-2,686.1	-242.2
Effect of exchange rate on cash eq.	-124.6%	-5.9	29	73
Net change in cash and cash eq.	114.5%	133	-907.3	3.2

Valuation
Market Cap	1 LCr
Price/Earnings (Trailing)	18.36
Price/Sales (Trailing)	3.12
EV/EBITDA	10.93
Price/Free Cashflow	35.77
MarketCap/EBT	13.78

Fundamentals
Revenue (TTM)	32.07 kCr
Rev. Growth (Yr)	14.47%
Rev. Growth (Qtr)	2.23%
Earnings (TTM)	5.45 kCr
Earnings Growth (Yr)	1.69%
Earnings Growth (Qtr)	4.64%

Profitability
Operating Margin	22.64%
EBT Margin	22.64%
Return on Equity	17.49%
Return on Assets	11.66%
Free Cashflow Yield	2.8%

Revenue Breakdown

Analysis of Dr. Reddy's Lab's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.

Revenue

Last Updated: Dec 31, 2024

Description	Share	Value
Global Generics	86.0%	7.4 kCr
Pharmaceutical Services and Active Ingredients	12.1%	1 kCr
Others	1.9%	161.4 Cr
Total		8.6 kCr

Share Holdings

Understand Dr. Reddy's Lab ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

As of 2025-03-31

Shareholder Name	Holding %
J P Morgan Chase Bank NA	11.54%
G V PRASAD	11.52%
SATISH REDDY KALLAM	10.27%
LIFE INSURANCE CORPORATION OF INDIA P & GS FUND	7.19%
KALLAM SATISH REDDY HUF	3.31%
NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2	2.45%
GUNUPATI VENKATESWARA PRASAD HUF	1.52%
Clearing Members	0.13%
Unclaimed or Suspense or Escrow Account	0.03%
ANURADHA GUNUPATI	0.01%
VSD Holdings & Advisory LLP	0%
APS Trust	0%
K SHRAVYA REDDY	0%
K VISHAL REDDY	0%
SHARATHCHANDRA REDDY GUNUPATI	0%
GUNUPATI MALLIKA REDDY	0%
DEEPTI REDDY KALLAM	0%
G VANI SANJANA REDDY	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Balance Sheet for Dr. Reddy's Lab

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	-51.5%	98	201	112	112	521	1,160
Current investments	-38.5%	2,533	4,118	3,584	4,298	1,233	1,912
Total current financial assets	-13.1%	10,591	12,183	11,089	9,526	8,302	9,135
Inventories	13.7%	4,568	4,019	3,614	3,043	3,052	3,348
Current tax assets	-	0	-	0	255	209	312
Total current assets	-4.9%	16,945	17,816	16,181	14,043	12,826	13,792
Property, plant and equipment	6.5%	5,442	5,109	4,801	4,738	4,298	4,024
Capital work-in-progress	34.4%	1,575	1,172	1,048	899	1,048	1,186
Goodwill	0%	85	85	85	85	85	85
Non-current investments	211.3%	9,969	3,203	3,303	3,142	3,227	3,024
Loans, non-current	-99.2%	1.5	62	61	1.1	7	1.2
Total non-current financial assets	199.7%	10,057	3,356	3,418	3,197	3,285	3,282
Total non-current assets	57.2%	19,714	12,543	11,806	11,332	11,239	10,700
Total assets	20.8%	36,660	30,359	27,986	25,375	24,067	24,496
Borrowings, non-current	-	0	0	44	29	26	20
Total non-current financial liabilities	-4.1%	48	50	44	29	109	104
Provisions, non-current	-1.2%	9.2	9.3	7.9	7.9	10	10
Total non-current liabilities	12.6%	653	580	567	461	371	114
Borrowings, current	423.1%	3,710	710	36	22	319	2,171
Total current financial liabilities	73.5%	7,841	4,520	3,649	3,337	3,557	5,114
Provisions, current	-9.2%	298	328	298	305	342	322
Current tax liabilities	515.2%	407	67	179	0	-	-
Total current liabilities	64.3%	9,099	5,538	4,701	4,440	4,442	6,045
Total liabilities	59.4%	9,752	6,118	5,268	4,901	4,813	6,159
Equity share capital	0%	83	83	83	83	83	83
Total equity	11%	26,908	24,241	22,718	20,474	19,254	18,336
Total equity and liabilities	20.8%	36,660	30,359	27,986	25,375	24,067	24,496

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	59.4%	1,133	711	1,354	578	910	1,485
Current investments	-30.4%	3,065	4,405	3,865	4,450	1,379	2,017
Total current financial assets	-8%	15,125	16,432	14,296	14,046	10,791	11,461
Inventories	13.4%	7,204	6,355	5,659	4,867	4,904	5,088
Current tax assets	-	228	-	30	269	307	328
Total current assets	1%	25,048	24,805	21,770	20,694	17,561	18,111
Property, plant and equipment	7.6%	6,726	6,249	5,850	5,654	5,167	4,887
Capital work-in-progress	37.1%	1,852	1,351	1,151	975	1,161	1,280
Goodwill	139.5%	1,316	550	541	547	522	547
Non-current investments	13.3%	120	106	186	66	173	167
Total non-current financial assets	4.4%	237	227	259	139	340	450
Total non-current assets	54.2%	21,681	14,058	13,040	11,591	11,608	11,636
Total assets	20.2%	46,728	38,864	34,809	32,285	29,169	29,747
Borrowings, non-current	0%	380	380	604	128	180	575
Total non-current financial liabilities	69.9%	1,017	599	604	128	185	575
Provisions, non-current	-104.3%	0	24	19	20	27	26
Total non-current liabilities	161.1%	2,664	1,021	906	427	407	769
Borrowings, current	214.8%	4,002	1,272	719	1,219	1,549	2,708
Total current financial liabilities	43.2%	10,765	7,518	6,337	6,419	6,327	7,607
Provisions, current	-8.1%	636	692	630	652	625	587
Current tax liabilities	118%	509	234	398	214	126	544
Total current liabilities	34.8%	12,921	9,588	8,406	8,572	7,987	9,766
Total liabilities	46.9%	15,585	10,609	9,313	8,999	8,394	10,534
Equity share capital	0%	83	83	83	83	83	83
Non controlling interest	-	394	0	0	-	0	0
Total equity	10.2%	31,143	28,255	25,497	23,286	20,775	19,212
Total equity and liabilities	20.2%	46,728	38,864	34,809	32,285	29,169	29,747

Is Dr. Reddy's Lab Better than it's peers?

Detailed comparison of Dr. Reddy's Lab against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical IndustriesPharmaceuticals	4.42 LCr	53.56 kCr	+6.16%	+22.24%	38.52	8.25	+10.28%	+28.38%
DIVISLAB	Divi's LabPharmaceuticals	1.6 LCr	9.42 kCr	+4.55%	+50.34%	77.55	17.01	+20.50%	+49.46%
CIPLA	CiplaPharmaceuticals	1.26 LCr	27.8 kCr	+7.81%	+10.34%	25.18	4.52	+7.01%	+33.22%
LUPIN	LupinPharmaceuticals	96.06 kCr	22.19 kCr	+3.82%	+30.29%	33.21	4.33	+13.18%	+59.81%
AUROPHARMA	Aurobindo PharmaPharmaceuticals	72.44 kCr	31.57 kCr	+7.47%	+10.24%	20.77	2.29	+10.80%	+26.04%

Income Statement for Dr. Reddy's Lab

Standalone figures (in Rs. Crores) / View Consolidated Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	-25.1%	5,015	6,696	5,841	5,105	4,103	4,839
Other Income	13%	235	208	218	213	228	223
Total Income	-24%	5,250	6,904	6,059	5,318	4,331	5,062
Cost of Materials	8.4%	1,012	934	911	908	819	751
Purchases of stock-in-trade	-22.6%	508	656	740	546	557	499
Employee Expense	-5.5%	794	840	856	780	782	784
Finance costs	55.6%	43	28	7.1	5.9	5.6	5.8
Depreciation and Amortization	1.9%	265	260	250	246	246	246
Other expenses	-5.6%	1,545	1,637	1,507	1,545	1,354	1,281
Total Expenses	-3.1%	4,131	4,263	4,145	3,978	3,699	3,461
Profit Before exceptional items and Tax	-57.7%	1,119	2,641	1,914	1,339	632	1,601
Total profit before tax	-57.7%	1,119	2,641	1,914	1,339	632	1,601
Current tax	-63.7%	256	703	467	270	157	396
Deferred tax	-75.9%	14	55	30	34	-0.2	12
Total tax	-64.5%	270	759	497	304	157	408
Total profit (loss) for period	-54.9%	849	1,882	1,417	1,035	475	1,193
Other comp. income net of taxes	-680.3%	-58.3	-6.6	4.1	-12	1	-60
Total Comprehensive Income	-57.9%	791	1,876	1,421	1,023	476	1,133
Earnings Per Share, Basic	161.4%	10.2	4.52	17.02	12.428	5.71	14.336
Earnings Per Share, Diluted	161.4%	10.18	4.512	16.994	12.408	5.7	14.308

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	14.9%	19,484	16,962	14,405	13,349	11,850	10,626
Other Income	45.9%	862	591	482	801	743	238
Total Income	15.9%	20,346	17,554	14,887	14,150	12,594	10,864
Cost of Materials	4.1%	3,292	3,161	3,378	3,266	2,556	2,103
Purchases of stock-in-trade	11.7%	1,987	1,779	2,057	1,252	1,117	869
Employee Expense	8.9%	3,086	2,833	2,435	2,270	2,030	1,932
Finance costs	31.2%	22	17	38	47	48	57
Depreciation and Amortization	5.7%	976	923	814	835	789	781
Other expenses	12.1%	5,432	4,845	4,331	3,819	3,377	3,356
Total Expenses	6.3%	14,555	13,688	12,663	11,094	9,818	9,163
Profit Before exceptional items and Tax	49.8%	5,791	3,866	2,224	3,056	2,776	1,701
Total profit before tax	49.8%	5,791	3,866	2,224	3,056	2,776	1,701
Current tax	57.7%	1,362	864	393	540	484	282
Deferred tax	-77.6%	88	389	208	330	-645.8	142
Total tax	15.7%	1,449	1,253	601	870	-161.9	423
Total profit (loss) for period	66.2%	4,342	2,613	1,623	2,186	2,938	1,277
Other comp. income net of taxes	39.7%	-31.8	-53.4	51	54	-43.6	14
Total Comprehensive Income	68.5%	4,310	2,559	1,674	2,240	2,894	1,291
Earnings Per Share, Basic	68%	52.19	31.474	19.57	26.368	35.446	15.396
Earnings Per Share, Diluted	68%	52.092	31.406	19.516	26.292	35.376	15.37

Consolidated figures (in Rs. Crores) / View Standalone Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	4.3%	8,381	8,038	7,696	7,114	7,237	6,903
Other Income	-51.5%	150	308	187	198	216	315
Total Income	2.2%	8,531	8,346	7,883	7,311	7,453	7,218
Cost of Materials	12.9%	1,453	1,287	1,227	1,096	1,141	956
Purchases of stock-in-trade	-18.1%	1,051	1,283	1,380	1,176	1,208	1,138
Employee Expense	-2.4%	1,366	1,399	1,414	1,284	1,276	1,280
Finance costs	8%	82	76	60	59	39	35
Depreciation and Amortization	18.7%	471	397	381	368	374	376
Other expenses	-1.6%	2,160	2,196	1,971	1,907	1,761	1,611
Total Expenses	3.5%	6,661	6,434	6,007	5,710	5,627	5,305
Profit Before exceptional items and Tax	-2.1%	1,870	1,911	1,877	1,602	1,826	1,912
Total profit before tax	-2.1%	1,870	1,911	1,877	1,602	1,826	1,912
Current tax	-30.9%	533	771	522	282	354	590
Deferred tax	67.5%	-62.9	-195.8	-31.3	13	94	-155.6
Total tax	-18.4%	470	576	490	295	448	434
Total profit (loss) for period	4.6%	1,404	1,342	1,392	1,310	1,381	1,482
Other comp. income net of taxes	-168.9%	-202.4	296	1.8	-55.7	99	-113.4
Total Comprehensive Income	-26.6%	1,202	1,638	1,394	1,254	1,480	1,369
Earnings Per Share, Basic	692.2%	16.97	3.016	16.722	15.732	16.588	17.818
Earnings Per Share, Diluted	693%	16.94	3.01	16.696	15.706	16.562	17.782

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	13.5%	28,011	24,670	21,545	19,048	17,517	15,448
Other Income	-15.4%	894	1,056	484	291	621	338
Total Income	12.4%	28,905	25,725	22,030	19,339	18,138	15,786
Cost of Materials	6.4%	4,490	4,220	4,312	4,296	2,985	2,889
Purchases of stock-in-trade	30.7%	4,399	3,367	3,484	2,574	2,546	1,881
Employee Expense	8.2%	5,030	4,647	3,886	3,630	3,380	3,356
Finance costs	19.7%	171	143	96	97	98	89
Depreciation and Amortization	17.6%	1,470	1,250	1,165	1,229	1,163	1,135
Other expenses	13.7%	6,839	6,016	6,450	5,469	6,112	4,419
Total Expenses	10.2%	21,719	19,714	19,038	16,503	16,308	13,494
Profit Before exceptional items and Tax	19.5%	7,186	6,012	2,991	2,836	1,830	2,292
Total profit before tax	19.5%	7,186	6,012	2,991	2,836	1,830	2,292
Current tax	139.2%	1,946	814	1,101	817	662	471
Deferred tax	-144.6%	-322.8	727	-222.4	115	-801.9	-84.9
Total tax	5.3%	1,623	1,541	879	932	-140.3	386
Total profit (loss) for period	23.8%	5,578	4,507	2,182	1,952	2,026	1,950
Other comp. income net of taxes	-408.4%	-65.6	-12.1	-289.8	540	-65	-108.7
Total Comprehensive Income	22.6%	5,512	4,495	1,893	2,492	1,961	1,841
Earnings Per Share, Basic	23.9%	67.044	54.294	26.314	23.534	24.444	23.506
Earnings Per Share, Diluted	24%	66.918	54.18	26.242	23.468	24.398	23.466

Investor Care
Dividend Yield	0.60%
Dividend/Share (TTM)	8
Shares Dilution (1Y)	0.05%
Diluted EPS (TTM)	52.35

Financial Health
Current Ratio	1.94
Debt/Equity	0.14
Debt/Cashflow	2.75

Price to Sales Ratio

Latest reported: ₹3

Revenue (Last 12 mths)

Latest reported: ₹32 kCr

Net Income (Last 12 mths)

Latest reported: ₹5 kCr

DRREDDY - Dr. Reddy's Laboratories Ltd. Share Price

What does Dr. Reddy's Laboratories Ltd. do?

The Bad News

The Good News

Valuation

Fundamentals

Profitability

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Investor Care

Financial Health

Updates from Dr. Reddy's Lab

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)